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Summary The cytotoxicity of paclitaxel against eight human tumour cell lines has been studied with in vitro
clonogenic assays. The fraction of surviving cells fell sharply after exposure for 24 h to paclitaxel concentra-
tions ranging from 2 to 20 nM; the paclitaxel IC50 was found to range between 2.5 and 7.5 nM. Increasing the
paclitaxel concentration above 50 nm, however, resulted in no additional cytotoxicity after a 24 h drug
exposure. Cells incubated in very high concentrations of paclitaxel (10,000 nM) had an increase in survival
compared with cells treated with lower concentrations of the drug. Prolonging the time of exposure of cells to
paclitaxel from 24 to 72 h increased cytotoxicity from 5 to 200 fold in different cell lines. Exponentially
growing cells were more sensitive to paclitaxel than were cells in the plateau phase of growth. Cremophor EL,
the diluent in which the clinical preparation of paclitaxel is formulated, antagonised paclitaxel at concentra-
tions of 0.135% (v/v). These data suggest that paclitaxel will be most effective clinically when there is
prolonged exposure of tumour to the drug. Further, it appears that modest concentrations (i.e., 50 nM) should
be as effective as higher concentrations of paclitaxel. Finally, we have noted that Cremophor EL is a
biologically active diluent and, at high concentrations (0.135% v/v), can antagonise paclitaxel cytotox-
icity.
Paclitaxel is a novel chemotherapeutic agent that is derived
from the bark of the Western Yew tree (Schiff et al., 1979;
Manfredi & Horwitz, 1984). In clinical trials, paclitaxel has
shown promising activity against ovarian (McGuire et al.,
1989) and breast cancers (Holmes et al., 1991). Paclitaxel also
appears to be active against a number of other human malig-
nancies, including leukaemia (Rowinsky et al., 1989) and
non-small cell lung cancer (Chang et al., 1992). In preclinical
testing in mouse xenograft tumour models, paclitaxel was
also active against a variety of human tumour cell lines,
including melanoma and colon adenocarcinoma (Riondel et
al., 1986).
Despite extensive investigations of the properties of pacli-
taxel over the last decade, few studies have examined the
cytotoxicity of paclitaxel by in vitro clonogenic assays
(Rowinsky et al., 1988). Most pre-clinical studies of pacli-
taxel have utilised growth inhibition assays (Rowinsky et al.,
1990). Though growth inhibition assays are valuable tools for
the rapid screening of cytotoxic agents (Carmichael et al.,
1987), cell survival assays are more sensitive and can define a
real dose-response relationship (Cook & Mitchell, 1989).
Recent studies of paclitaxel in Chinese hamster V79 cells
demonstrated an unusual dose-response relationship for pac-
litaxel cytotoxicity (Cook et al., 1993). After 24 h of exposure
to paclitaxel, low concentrations (10 nM to 100 nM) of the
drug resulted in a steep decline in cell survival. Further
increasing the paclitaxel concentration from 250 nM to
10,000 nM actually resulted in an increase in survival of these
rodent cells. Different cell cycle blocks and delays were noted
depending on the concentrations of paclitaxel used. Addi-
tionally, cells in plateau phase were completely protected
from paclitaxel cytotoxicity.
Our observations in V79 cells have led us to undertake
similar studies in a variety of human tumour cell lines. The
results of our current studies of paclitaxel cytotoxicity raise
questions about the importance of the dose intensity of pacli-
taxel that is delivered to cells (or patients). Our results also
suggest that the diluent employed in the clinical formulation
of paclitaxel, Cremophor EL, may independently affect
tumour cells; the effects of Cremophor EL could have an
impact on the clinical efficiency of paclitaxel.
Materials and methods
Chemicals
Paclitaxel powder and Cremophor EL were supplied by the
Cancer Therapy Evaluation Program (CTEP), National
Cancer Institute. The powder was dissolved in dimethyl sul-
foxide (DMSO, Sigma Chemical Co., St Louis, MO.) to a
stock concentration of 10 mM. Paclitaxel formulated in
Cremophor EL was obtained from the Pharmacy Branch of
the Clinical Center at the NIH at a stock concentration of
6 mg ml-' (7.04 mM). Unless specifically noted otherwise, all
studies used paclitaxel formulated in Cremophor EL.
Cell culture
All cell lines used in these studies were of human origin. The
breast adenocarcinoma MCF-7, lung adenocarcinoma A549,
cervical carcinoma HeLa, grade III astrocytoma U373, and
colon adenocarcinoma HT-29 cell lines were all obtained
from ATCC (Rockville, MD). The ovarian adenocarcinoma
OVG-1 cell line was established in the laboratory of the
Radiation Oncology Branch from patient material taken at
the Clinical Center of the NIH. The pancreatic adenocar-
cinomas PC-Sh and PC-Zd cell lines were established and
kindly provided to us by Dr William Sindelar of the Surgery
Branch from surgical specimens taken at the Clinical Center of
the NIH. MCF-7, A549, HeLa, HT-29, and OVG-1 were all
maintained in RPMI 1640 medium supplemented with 10%
foetal bovine serum (FBS) and antibiotics. U373, PC-Sh, and
PC-Zd were grown in Dulbecco's modified minimal essential
medium (DMEM) supplemented with 20% FBS and anti-
biotics. For cell survival experiments, a number of 100 mm
petri dishes were plated with 5 x 105 cells. Exponentially
growing cells were exposed to various concentrations of pac-
litaxel or its appropriate diluent 24 h later. For experiments
that studied cells in plateau phase of growth, cells were
permitted to grow for a minimum of 72 h before they were
exposed to paclitaxel. Cell counts of cultures grown in
parallel confirmed no net growth of cells in cultures used in
plateau phase experiments. Additionally, DNA flow cyto-
metry studies demonstrated that 75-80% of cells in plateau
phase cultures were in GI, compared to only 45-47% of cells
in exponentially growing cultures. After exposure to pacli-
taxel for various times, the cells were rinsed, trypsinised, and
washed with medium. The cells were re-suspended as single
cell suspensions, counted with a particle counter (Elzone®
18OXY; Particle Data Inc., Elmhirst, IL), plated, and incu-
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bated for macroscopic colony formation. Following a one to
two week incubation, colonies were fixed with methanol/
acetic acid (3: 1), stained with crystal violet, and colonies with
> 50 cells counted. All survival points were done in triplicate
and experiments were conducted a minimum of two times.
Error bars shown in the Figures represent s.e.m. and are
shown when larger than the symbol. Plating efficiencies for
cells were in the following ranges: MCF-7, 45-60%; A549,
40-50%; OVG-1, 40-50%; PC-Sh, 40-50%; PC-Zd,
40-50%; HeLa, 75-85%; U373, 15-25%; and HT-29,
35-45%. Plating efficiencies of all cell lines used in these
studies were unaffected by cell density.
Results
Cell survival
All exponentially growing human tumour cell lines exposed
for 24 h to paclitaxel formulated in Cremophor EL exhibited
characteristic dose-response curves (Figures 1 and 2). These
curves were distinguished by an initial steep decline in cell
survival such that the IC50 for most of the cell lines ranged
between paclitaxel concentrations of 2.5 nM and 7.5 nM
(Table I). Above paclitaxel concentrations of 50nM, how-
ever, survival remained constant in all cell lines. No addi-
tional cell killing was observed in any of the cell lines
exposed to paclitaxel for 24 h when paclitaxel concentrations
ranged from 50 nM to 10,000 nM (200 fold range in concent-
ration). Several cell lines showed an enhanced cell survival
when the concentration of paclitaxel was 10,000 nM. This
improvement in cell survival at very high concentrations of
paclitaxel was most marked in the A549 cell line.
Because the possibility existed that the enhancement of
survival seen at 10,000 nM paclitaxel was due to the large
amount of Cremophor EL (0.135% v/v) added to the cells,
A549 and MCF-7 cells were exposed to relatively low con-
centrations of paclitaxel (< 20 nM) for 24 h (Figure 2). As
noted previously, cells showed a sharp decline in survival
with increasing concentrations of paclitaxel up to 20 nM.
However, cells incubated in the same low paclitaxel levels in
the presence of 0.135% v/v Cremophor EL - the same
concentration of Cremophor El present in a solution of
10,000 nM paclitaxel - showed a marked reduction in cyto-
toxicity. A similar set of experiments in which cell lines were
exposed to paclitaxel in high levels of DMSO (0.135% v/v)
showed no effect of DMSO on paclitaxel cytotoxicity (data
not shown). Neither diluent alone had any effect on cell
survival at concentrations up to 0.135% v/v (note that
plating efficiency of cells in Figure 2 is unaffected by
Cremophor EL; data for DMSO are not shown). Further
evidence of the ability of high levels of Cremophor EL to
abrogate paclitaxel cytotoxicity in A549 cells is shown in
Figure 3. A549 cells were treated with increasing concentra-
tions of paclitaxel that had been dissolved in DMSO. DMSO
did not alter either the initial decline in cell survival at low
concentrations of paclitaxel or the uniform cytotoxicity that
occurs between 25 nM and 1000 nM. However, the paradox-
ical increase in survival seen at very high concentrations of
paclitaxel was affected by the choice of diluent. No increase
in survival in A549 cells was seen at 10,000 nM paclitaxel,
when the drug was dissolved in DMSO.
As dose-response curves for 24 h paclitaxel exposure
demonstrated little effect of increased concentration on
cytotoxicity, studies were carried out to examine the effect of
prolonged paclitaxel exposure on cell survival. Cells were
incubated in 5 or 50 nM paclitaxel for periods ranging from 6
to 72 h. Figure 4 shows that cells suffered little or no
cytotoxicity when exposed to paclitaxel for only 6 h, and
greatly reduced cytotoxicity after 12 h compared to 24 h of
paclitaxel treatment. Further exposure to paclitaxel for 48 or
72 h resulted in increased cytotoxicity in cells exposed to
50 nM paclitaxel. The enhancement of cytotoxicity with in-
creasing time of exposure to paclitaxel varied among cell
lines; MCF-7 cells had only a 5-fold increase in cell kill while
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Figure 1 Survival of four human tumour cell lines after exposure
to paclitaxel for 24 h. Points represent the means of at least three
replicates. Error bars are s.e.m.
c
0
C.)
Co
.)
C
cJ
C,)
0)
c
._
2.
0)
C,)
a
b
Paclitaxel (nM)
Figure 2 Survival of A549 (a) and MCF-7 (b) cells exposed to
paclitaxel for 24 h. As described in Materials and methods, cells
were exposed to either paclitaxel diluted in RPMI or paclitaxel
diluted in medium to which Cremophor EL had been added to a
final concentration of 0.135% (v/v) - the same concentration of
Cremophor EL which is present in a 10jLM solution ofpaclitaxel.
Points represent the mean of at least three replicates. Error bars
are s.e.m. Plating efficiency for control A549 cells was 43% and
for control MCF-7 cells was 60%. Plating efficiency for A549
and MCF-7 cells exposed to 0.135% v/v Cremophor EL was
43% and 57%, respectively.1106 J.E. LIEBMANN et al.
Table I Concentration of paclitaxel required to kill 50% of cells in
exponentially growing cultures after a 24 h exposure to the drug
Cell lines Tumour type ICSO (nM)
HeLa Cervical carcinoma 2.6
A549 Lung adenocarcinoma 4.1
U373 Grade III astrocytoma 4.2
MCF-7 Breast adenocarcinoma 2.5
HT-29 Colon adenocarcinoma 2.8
OVG-1 Ovarian carcinoma 4.0
PC-Sh Pancreatic adenocarcinoma 7.5
PC-Zr Pancreatic adenocarcinoma 4.0
Each value represents the mean of at least two experiments.
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Figure 3 Survival of A549 cells after exposure for 24 h to pac-
litaxel. Paclitaxel was formulated initially at a concentration of
6 mg ml- in Cremophor EL or DMSO and then diluted in RPMI
medium. Points represent the means of at least three replicates.
Error bars depict s.e.m.
A549 cells had a 2 log increase in cytotoxicity at 72 h com-
pared to 24 h of paciitaxel exposure. In contrast to the
enhanced cytotoxicity seen with prolonged incubation of cells
in 50 nM paclitaxel, continuous incubation in 5 nM paclitaxel
resulted in little additional cell kill after 24 h of exposure.
The issue of the effect of increasing paclitaxel concentra-
tion combined with increasing duration of exposure to the
drug on cytotoxicity is addressed in Figure 5. Little or no
increased cell killing was observed in cell lines exposed to
paclitaxel concentrations of more than 50 nM even after 48 or
72 h of drug exposure. The marked increase in cell survival
noted after a 24 h exposure to 10,000 nM paclitaxel was
maintained at the later time points.
In contrast to exponentially growing cells, cells that were
permitted to grow to plateau phase were relatively resistant
to paclitaxel (Figure 6). The initial decline in survival seen
with increasing paclitaxel concentrations in exponentially
growing cultures was altered in plateau phase cells leading to
an increase in the IC50 for all cell lines. Additionally, the
stable nadir in cell survival seen with increasing concentra-
tions of paclitaxel was also markedly increased in plateau
phase cells compared with exponentially growing cells.
Discussion
We have shown, in a variety of different human tumour cell
lines, that paclitaxel has a unique dose-response cytotoxic
effect. All lines exposed to paclitaxel for 24 h that we have
studied thus far exhibit a sharp decline in cell survival at low
concentrations of the drug. However, each line also demon-
strated a plateau in survival at concentrations of paclitaxel
above 50 nM. At a very high concentration of paclitaxel,
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Figure 4 Survival of A549 (a) MCF-7 (b), and PC-Sh (c) cells
after exposure to 5 nm or 50 nM paclitaxel for up to 72 h. Points
represent the means of at least three replicates. Error bars depict
s.e.m.
10,000 nM, several cell lines showed an increase in cell sur-
vival. The increase in cell survival at 10,000 nM paclitaxel
may have been due largely to the high concentration of
Cremophor EL (0.135% v/v) present. The shape of the dose-
response curves observed at paclitaxel concentrations of less
than 1000 nM - that is, an initially steep decline in survival
followed by a plateau in cytotoxicity at higher doses - has
been reported with other drugs, including the vinca alkaloids
(Hill & Whelan, 1981). However, we are not aware of any
reports showing dramatic increases in survival of cells
exposed to increasing amounts of cytotoxic drugs as we have
observed in cells exposed to 10,000 nM paclitaxel.
The concentrations of paclitaxel that we have used in these
studies are similar to plasma concentrations of the drug that
have been achieved in clinical trials (Rowinsky et al., 1990).
Brief (one to six hour) infusions of paclitaxel have resulted in
peak plasma concentrations of 1000 to 10,000 nM. When
paclitaxel has been given over 24 h, peak plasma levels have
ranged from 600 to 3500 nM. More recently, paclitaxel steady
state plasma levels obtained during a 96 h infusion of the
drug have been described (Wilson et al., 1993) and range
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Figure 5 Survival of A549 (a) and MCF-7 (b) cells after expo-
sure to various concentrations of paclitaxel for 24, 48, or 72 h.
Points represent the means of at least three replicates. Error bars
depict s.e.m.
from 53 to 77 nM. Given that the terminal half-life of pacli-
taxel in plasma ranges from five to eight hours (Rowinsky et
al., 1990), the concentrations and durations of exposure of
the drug that we have used in vitro approximate what has
been achieved clinically in plasma.
Though cells exposed to various concentrations of pac-
litaxel for a fixed period of time (24 h) showed no increase in
cytotoxicity in response to drug concentrations above 50 nM,
increasing the time of exposure to paclitaxel did result in a
marked increase in cytotoxicity. Little or no cytotoxicity was
seen in cells that were treated with paclitaxel for less than
12 h. Cytotoxicity then increased in all cell lines as time of
exposure to paclitaxel increased, so that cell killing after 72 h
was as much as 200 times greater than that seen after 24 h of
paclitaxel treatment. However, even at exposure times of
72 h, little or no additional cytotoxicity was achieved when
paclitaxel concentrations were raised above 50 nM. These
results show that cytotoxicity due to paclitaxel is very depen-
dent on the duration of exposure to the drug and less depen-
dent on the concentration of paclitaxel to which cells are
exposed.
We believe that these findings lead to two conclusions
which have profound implications for the clinical use of
paclitaxel. First, achieving peak tumour drug levels above
50 nM paclitaxel is unlikely to be rewarded with increased
tumour response. Second, extended exposure to paclitaxel is
likely to result in a greater tumour response than would be
expected from the administration of bolus doses of the drug.
These conclusions imply that the optimal delivery of pac-
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Figure 6 Survival of A549 (a) and MCF-7 (b) cells after expo-
sure to paclitaxel for 24 h. As described in Materials and
methods, either exponentially growing cell cultures in plateau
phase of growth were exposed to paclitaxel and survival was
assessed by clonogenic assay. Points represent the means of at
least three replicates. Error bars are s.e.m.
litaxel to most patients would be via a prolonged continuous
infusion with the goal of achieving steady state drug levels of
about 50 nM. It should be stressed that an exact in vivo
steady state plasma drug level target can not be determined
directly from our in vitro data - plasma levels may not reflect
tumour drug levels. For example, recent pharmacokinetic
data (Markman et al., 1992) have shown that intraperitoneal
paclitaxel levels are maintained far longer than in plasma.
However, in no exponentially growing human tumour cell
line that we have studied have we seen enhanced cytotoxicity
with paclitaxel concentrations over 50 nM. (N.B., this state-
ment applies only to tumour lines that are not resistant to
paclitaxel; we, and others (Horwitz et al., 1986), have found
that cells that express the multiple drug resistance phenotype
are markedly resistant to high (1000 nM) concentrations of
paclitaxel.)
The current data are also consistent with results that have
been reported from clinical trials. We have found that pac-
litaxel is an active agent against a variety of different human
tumour cells. However, in the absence of prolonged exposure
of cells to paclitaxel, we have found surviving fractions of
0.01 to 0.1 in cells exposed to clinically relevant concentra-
tions of paclitaxel for 24 h. To date, the overwhelming
majority of clinical responses reported after the use of single
agent paclitaxel have been partial responses and have been of
brief - less than one year - duration (McGuire et al., 1989;
Holmes et al., 1991). Although overall response rates in
clinical trials of paclitaxel in breast and ovarian cancer have
been impressive, the large proportion of partial responses
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and the brief nature of most responses suggest that a con-
siderable amount of viable tumour remains after single agent
paclitaxel therapy.
Non-proliferating cells were markedly more resistant to
paclitaxel than were cells growing exponentially. Similar find-
ings have recently been reported in N417 small cell lung
cancer cells (Riou et al., 1992). It has been recognised for
some time that cell cycle specific chemotherapeutic agents are
less toxic to non-proliferating cells (Drewinko et al., 1981)
and paclitaxel fits this pattern very well. It is possible that
plateau phase cells that are exposed to paclitaxel for longer
durations would suffer more cytotoxicity than we found after
a 24 h exposure to the drug. However, because of the diffi-
culty of maintaining cells in plateau phase in culture for
prolonged periods of time, we were unable to test the hypo-
thesis that prolonged exposure to paclitaxel increases the
killing of plateau phase cells in our in vitro systems.
Cremophor EL, the diluent in which paclitaxel is prepared
for clinical use, has been shown to be a protein kinase C
inhibitor in cell extracts (Chaung et al., 1991) and may be
able to reverse the multiple drug resistance phenotype
(Woodcock et al., 1990). Our studies confirm that this diluent
has biologic effects, but suggest that high levels of Cremo-
phor can antagonise the cytotoxicity of paclitaxel. Concen-
trations of Cremophor EL, equivalent to that which would
be present in a 10,000 nM solution ofpaclitaxel, inhibited the
cytotoxicity normally seen after cells are exposed to pac-
litaxel for 24 h (Figure 2). High levels ofDMSO did not alter
paclitaxel cytotoxicity. A possible explanation for the
antagonistic effect of high levels of Cremophor EL on pac-
litaxel cytotoxicity can be found in DNA flow cytometry
studies ofA549 cells (Liebmann et al., 1993b). We and others
(Schiff & Horwitz, 1980) have found that exposure of expon-
entially dividing cells to paclitaxel rapidly results in a block
in the G2/M phases of the cell cycle. However, a significant
fraction of A549 cells exposed to paclitaxel in a high concen-
tration of Cremophor EL remain in GI instead of progress-
ing to a block in G2/M (Liebmann et al., 1993b). If
Cremophor EL is able to produce a GI block, then cells
would be unable to enter G2 and M where the cytotoxic
effect of paclitaxel is apparently manifest. We have seen a
similar antagonistic effect of paclitaxel cytotoxicity with
glutathione depletion by L-buthionine sulfoximine in A549
cells (Liebmann et al., 1993a).
It is unclear whether the in vitro conditions involving high
concentrations ofCremophor EL would be replicated in vivo.
There is considerable information about the pharmaco-
kinetics of paclitaxel from Phase I trials (Rowinsky et al.,
1990). Little is known about the pharmacokinetics of Cremo-
phor EL, but it seems unlikely that this diluent would persist
in plasma for a long period of time. Recently, however, there
has been a report of the intraperitoneal administration of
paclitaxel (Markman et al., 1992). In that study extraordin-
arily high concentrations of paclitaxel (>100,000 nM) were
obtained in the peritoneal space. If Cremophor EL is not
rapidly cleared from the peritoneum it may exert con-
siderable effects, possibly including the antagonism of pac-
litaxel cytotoxicity. Though this would be of concern for the
intra- peritoneal administration of paclitaxel, it would not be
unsurmountable. The half-life of paclitaxel is markedly pro-
longed in the peritoneum (Markman et al., 1992). Lower
doses of paclitaxel which resulted in lower peak levels of
paclitaxel (s<1000 nM) would still result in an extended
exposure of tumour to paclitaxel. Because of the time
dependency of paclitaxel cytotoxicity, this should provide
excellent tumour kill while avoiding potential problems from
high concentrations of Cremophor EL.
In summary, we have shown, with in vitro clonogenic
assays, that the dose-response curve of paclitaxel cytotoxicity
is initially steep at low concentrations of the drug, but then is
flat over a wide range of paclitaxel concentrations. Further,
at a very high concentration of paclitaxel (10,000 nM), cell
survival significantly increases compared with survival at
lower paclitaxel concentrations. By contrast, increasing the
time of paclitaxel exposure results in increasing paclitaxel
cytotoxicity. Cells in plateau phase of growth are much more
resistant to paclitaxel than are exponentially growing cells.
High levels of Cremophor EL, the diluent in which paclitaxel
is prepared for clinical use, can antagonise paclitaxel cytotox-
icity and may be responsible for the increase in cell survival
noted in cells exposed to 10,000 nM paclitaxel. These results
suggest that paclitaxel will be most effective clinically if it is
administered to patients with the goal of maintaining modest
plasma levels (about 50nM) for several days.
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